Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 4

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Authors Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Published 15 September 2007 Volume 2007:3(4) Pages 381—388

Jirar Topouchian1, Ramzi El Feghali1, Bruno Pannier1, Shuyu Wang2, Feng Zhao3, Karel Smetana4, Koon Teo3, Roland Asmar1

1The CardioVascular Institute, Paris, France; 2Beijing Clinical Trial and Research Center, Beijing, China; 3Population Health Research Institute, Hamilton, Canada; 4Vojenska nemocnice Plzen, Pizen, Czech Republic

Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiffness reduction is associated with an improvement in survival. Reduction of arterial stiffness by pharmacological drugs varies according to the drugs and doses used and duration of treatment. This effect on the arteries differs among the various classes of drugs and among individual drugs in the same class. Quantification of the stiffness and other properties of the arterial wall can be used to monitor the responses to therapy in individuals with hypertension and other cardiovascular diseases. These measures can then be used as surrogate markers for the risk of clinical events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective effects of RAS inhibition are partly independent from blood pressure reduction and related to several mechanisms including vascular protective effects. The aim of the TRanscend Arterial stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some clinical baseline data of the TRANS substudy are reported. When completed, the results of the TRANS substudy will show whether the beneficial effects of treatment with telmisartan on cardiovascular outcome may be related to an improvement in arterial stiffness.

Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, antihypertensive

Download Article [PDF] 

Readers of this article also read:

Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes

Cosco D, Federico C, Maiuolo J, Bulotta S, Molinaro R, Paolino D, Tassone P, Fresta M

International Journal of Nanomedicine 2014, 9:2359-2372

Published Date: 15 May 2014

The therapeutic effect of monocyte chemoattractant protein-1 delivered by an electrospun scaffold for hyperglycemia and nephrotic disorders

Yong C, Wang ZX, Zhang X, Shi XM, Ni ZJ, Fu H, Ding GS, Fu ZR, Yin H

International Journal of Nanomedicine 2014, 9:985-993

Published Date: 17 February 2014

Using poly(lactic-co-glycolic acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/polyethylenimine nanoparticles to promote bone formation in vitro and in vivo

Qiao C, Zhang K, Jin H, Miao L, Shi C, Liu X, Yuan A, Liu J, Li D, Zheng C, Zhang G, Li X, Yang B, Sun H

International Journal of Nanomedicine 2013, 8:2985-2995

Published Date: 13 August 2013

Current status of NADPH oxidase research in cardiovascular pharmacology

Rodiño-Janeiro BK, Paradela-Dobarro B, Castiñeiras-Landeira MI, Raposeiras-Roubín S, González-Juanatey JR, Álvarez E

Vascular Health and Risk Management 2013, 9:401-428

Published Date: 25 July 2013

Characterization, activity, and computer modeling of a molecular inclusion complex containing rifaldazine

Tan Q, He D, Wu M, Yang L, Ren Y, Liu J, Zhang J

International Journal of Nanomedicine 2013, 8:477-484

Published Date: 1 February 2013

Controlled release of 5-fluorouracil and progesterone from magnetic nanoaggregates

Ragab DM, Rohani S, Consta S

International Journal of Nanomedicine 2012, 7:3167-3189

Published Date: 29 June 2012

Acoustic cardiac signals analysis: a Kalman filter–based approach

Salleh SH, Hussain HS, Swee TT, Ting CM, Noor AM, Pipatsart S, Ali J, Yupapin PP

International Journal of Nanomedicine 2012, 7:2873-2881

Published Date: 11 June 2012

Antiplatelet combinations for prevention of atherothrombotic events

Mario Bollati, Fiorenzo Gaita, Matteo Anselmino

Vascular Health and Risk Management 2011, 7:23-30

Published Date: 12 January 2011

Current trends in drug treatment of obsessive–compulsive disorder

Eric H Decloedt, Dan J Stein

Neuropsychiatric Disease and Treatment 2010, 6:233-242

Published Date: 10 May 2010

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

Baptist Gallwitz

Vascular Health and Risk Management 2007, 3:203-210

Published Date: 15 May 2007